

# *Welcome to today's FDA/CDRH Webinar*

*Thank you for your patience while additional time is provided  
for participants to join the call.*

**Please connect to the audio portion of the webinar now:**

Zoom Webinar

Link: <https://fda.zoomgov.com/j/1600971341?pwd=UTJMTIZmYzVScmNZamd2d2J4SU92Zz09>

Webinar Passcode: \$vrC6z

Dial: 833-568-8864

Webinar ID: 160 097 1341

Passcode: 292602

# **Respirator Update: FDA No Longer Authorizes Use of Non-NIOSH-Approved or Decontaminated Disposable Respirators**

Office of Strategic Partnerships and Technology Innovation (OST)  
Center for Devices and Radiological Health (CDRH)  
U.S. Food and Drug Administration (FDA)

July 13, 2021

# Agenda

- Overview of FDA Letter to Health Care Personnel & Facilities
  - Background
  - NIOSH-Approved Respirators Authorized under Emergency Use Authorization (EUA)
  - Recommendations
  - FDA Actions
- Resources
- Questions

# Background

- On June 30, 2021, the FDA announced it is **revoking** the Emergency Use Authorizations (EUAs) for **non-NIOSH-approved disposable respirators** (revocation effective July 6, 2021) and the EUAs for **decontamination and bioburden reduction systems** (revocation effective June 30, 2021). **For ORP**
- These actions are in follow-up to the [May 27, 2021, letter](#) in which the FDA recommended a transition away from non-NIOSH-approved disposable respirators as well as from reusing decontaminated or bioburden-reduced disposable respirators.
- Based on the **increased domestic supply of respirators** approved by the Centers for Disease Control and Prevention's (CDC) National Institute for Occupational Safety and Health (NIOSH), and **consistent with [CDC's updated recommendations](#)** and **in alignment with** the Occupational Safety and Health Administration's (OSHA) **recently published [Emergency Temporary Standard \(ETS\)](#)** to protect health care workers, the **FDA believes health care facilities should not use crisis capacity strategies any longer.**

# NIOSH-Approved Respirators Authorized under EUA

- During the COVID-19 public health emergency, **NIOSH-approved respirators, including N95 respirators, are authorized\*** on a continual basis under the FDA emergency use authorization (EUA) for NIOSH-Approved air purifying respirators (includes single-use respirators and those designed to be reusable)
- There are **over 6,400 total respirator models or configurations on the NIOSH certified equipment list**, which meet the NIOSH-Approved EUA criteria and thus are FDA-authorized, including:
  - **Over 600 filtering facepiece respirators (FFR) models** (of which there are over 530 N95 FFR models)
  - **Over 5,500 elastomeric respirator configurations**, including new elastomeric respirators without an exhalation valve
  - **Over 360 powered air-purifying respirators (PAPR) configurations**

\* until the U.S. Department of Health and Human Services (HHS) Secretary's declaration that circumstances exist justifying authorization is terminated or the EUA is revoked

# Recommendations

- **The FDA recommends** that health care personnel and facilities:
  - **Use only FDA-cleared or NIOSH-approved respirators**, including N95s and other respirators under the Emergency Use Authorization (EUA) for [NIOSH-Approved Air Purifying Respirators for Use in Health Care Settings During Response to the COVID-19 Public Health Emergency](#).
  - **Transition from wearing disposable respirators for respiratory protection for an extended time to conventional capacity strategies** that include wearing a disposable respirator for each patient contact, according to the [CDC's strategies](#), as appropriate.

# Recommendations (cont.)

- **The FDA recommends** that health care personnel and facilities:
  - **Consider redistributing current inventory of non-NIOSH-approved respirators, such as, to:**
    - Non-health care settings for non-medical use (for example, construction)
    - Other countries in need (in accordance with the Federal Food, Drug, and Cosmetic Act export provisions)
    - While it is possible that non-NIOSH-approved respirators may be reconditioned for use as source control (see, for example as face masks in [Import Alert 89-18](#)), the FDA does not recommend that non-NIOSH-approved respirators undergo reconditioning at this time because there is currently sufficient supply of source control medical devices, among other things
  - **Continue to increase inventory of available NIOSH-approved respirators, including:**
    - N95s and other disposable filtering facepiece respirators (FFRs)
    - Elastomeric respirators, including new elastomeric respirators without an exhalation valve that can be used in an operating room
    - Powered air-purifying respirators (PAPRs).

# FDA Actions



- **On June 30, 2021, the FDA announced the [revocation](#) of the following EUAs:**
  - Imported, Non-NIOSH-Approved Disposable Filtering Facepiece Respirators (effective July 6, 2021)
  - Non-NIOSH-Approved Disposable Filtering Facepiece Respirators Manufactured in China (effective July 6, 2021)
  - Decontamination and Bioburden Reduction System EUAs for Personal Protective Equipment (effective June 30, 2021)
- **In addition, on June 30, 2021, the FDA has withdrawn two related decontamination and bioburden reduction guidance documents:**
  - Recommendations for Sponsors Requesting EUAs for Decontamination and Bioburden Reduction Systems for Face Masks and Respirators During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency: Guidance for Industry and Food and Drug Administration Staff
  - Enforcement Policy for Bioburden Reduction Systems Using Dry Heat to Support Single-User Reuse of Certain Filtering Facepiece Respirators During the Coronavirus Disease (2019) Public Health Emergency





## FDA Actions (cont.)

- The FDA **will continue to monitor supply and demand** to assess respirator availability as facilities systematically transition away from the most extreme measures of respirator conservation (that is, crisis capacity strategies) to contingency and conventional use.
- Respirators, specifically surgical respirators, presently **remain on the FDA's device shortage list**.
- The FDA **will continue to keep health care personnel and the public informed** if new or additional information becomes available.

# Resources

- FDA No Longer Authorizes Use of Non-NIOSH-Approved or Decontaminated Disposable Respirators - Letter to Health Care Personnel and Facilities:  
<https://www.fda.gov/medical-devices/letters-health-care-providers/update-fda-no-longer-authorizes-use-non-niosh-approved-or-decontaminated-disposable-respirators>  
FDA FAQs on the EUAs for Non-NIOSH Approved Respirators During the COVID-19 Pandemic
- <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/faqs-euas-non-niosh-approved-respirators-during-covid-19-pandemic>
- FDA Considerations for Selecting Respirators for Your Health Care Facility  
<https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/considerations-selecting-respirators-your-health-care-facility>
- CDC Strategies for Optimizing the Supply of N95 Respirators:  
<https://www.cdc.gov/coronavirus/2019-ncov/hcp/respirators-strategy/index.html>  
CDC Personal Protective Equipment (PPE) Burn Rate Calculator:  
<https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/burn-calculator.html>
- OSHA Occupational Exposure to COVID-19 Emergency Temporary Standard:  
<https://www.federalregister.gov/documents/2021/06/21/2021-12428/occupational-exposure-to-covid-19-emergency-temporary-standard>
- Overview of the OSHA Emergency Temporary Standard  
<https://www.osha.gov/coronavirus/ets>

# Questions?

Email: [CDRH-COVID19-SurgicalMasks@fda.hhs.gov](mailto:CDRH-COVID19-SurgicalMasks@fda.hhs.gov)

Slide Presentation, Transcript, and Webinar Recording  
will be available at:

[www.fda.gov/training/cdrhlearn](http://www.fda.gov/training/cdrhlearn)

Under Heading: Specialty Technical Topics and  
Sub-heading Personal Protective Equipment (PPE)

Please complete a short survey about your FDA CDRH webinar experience.

The survey can be found at [www.fda.gov/CDRHWebinar](http://www.fda.gov/CDRHWebinar)

immediately following the conclusion of the live webinar.